An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils

  1. Emil Dandanell Agerschou
  2. Patrick Flagmeier
  3. Theodora Saridaki
  4. Céline Galvagnion
  5. Daniel Komnig
  6. Laetitia Heid
  7. Vibha Prasad
  8. Hamed Shaykhalishahi
  9. Dieter Willbold
  10. Christopher M Dobson
  11. Aaron Voigt
  12. Björn Falkenburger  Is a corresponding author
  13. Wolfgang Hoyer  Is a corresponding author
  14. Alexander K Buell  Is a corresponding author
  1. Heinrich Heine University Düsseldorf, Germany
  2. University of Cambridge, United Kingdom
  3. RWTH Aachen University, Germany
  4. Technical University of Denmark, Denmark

Abstract

Removing or preventing the formation of α-synuclein aggregates is a plausible strategy against Parkinson's disease. To this end we have engineered the β-wrapin AS69 to bind monomeric α-synuclein with high affinity. In cultured cells, AS69 reduced the self-interaction of α-synuclein and the formation of visible α-synuclein aggregates. In flies, AS69 reduced α-synuclein aggregates and the locomotor deficit resulting from α-synuclein expression in neuronal cells. In biophysical experiments in vitro, AS69 highly sub-stoichiometrically inhibited both primary and autocatalytic secondary nucleation processes, even in the presence of a large excess of monomer. We present evidence that the AS69-α-synuclein complex, rather than the free AS69, is the inhibitory species responsible for sub-stoichiometric inhibition of secondary nucleation. These results represent a new paradigm that high affinity monomer binders can lead to strongly sub-stoichiometric inhibition of nucleation processes.

Data availability

- Numerical data represented in the graphs for cell culture and fly experiments will be made publicly available on osf.io as we did for previous publications.- The numerical data for the biophysical experiments will be made publicly available within the same repository on osf.io.- The raw images of the gels used in the publication will be made publicly available.All data have been deposited on osf.io ( https://osf.io/6n2gs/?view_only=7eb7024d8ecb460a817cd0ed35978339 ) and will be made available in the event of publication

The following data sets were generated

Article and author information

Author details

  1. Emil Dandanell Agerschou

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Patrick Flagmeier

    Department of Chemistry, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1204-5340
  3. Theodora Saridaki

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Céline Galvagnion

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Daniel Komnig

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6312-5236
  6. Laetitia Heid

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Vibha Prasad

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Hamed Shaykhalishahi

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Dieter Willbold

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0065-7366
  10. Christopher M Dobson

    Department of Chemistry, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Aaron Voigt

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0428-7462
  12. Björn Falkenburger

    Department of Neurology, RWTH Aachen University, Aachen, Germany
    For correspondence
    bfalkenburger@ukaachen.de
    Competing interests
    The authors declare that no competing interests exist.
  13. Wolfgang Hoyer

    Institute of Physical Biology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
    For correspondence
    wolfgang.hoyer@hhu.de
    Competing interests
    The authors declare that no competing interests exist.
  14. Alexander K Buell

    Biotechnology and Biomedicine, Technical University of Denmark, Kgs Lyngby, Denmark
    For correspondence
    alebu@dtu.dk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1161-3622

Funding

Leverhulme Trust

  • Alexander K Buell

Boehringer Ingelheim Fonds

  • Patrick Flagmeier

Studienstiftung des Deutschen Volkes

  • Patrick Flagmeier

Alexander von Humboldt-Stiftung

  • Céline Galvagnion

Parkinson's and Movement Disorder Foundation

  • Alexander K Buell

H2020 European Research Council (MCSA grant agreement No 706551)

  • Céline Galvagnion

Novo Nordisk Foundation

  • Alexander K Buell

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Andrew B West, Duke University, United States

Version history

  1. Received: February 25, 2019
  2. Accepted: August 4, 2019
  3. Accepted Manuscript published: August 7, 2019 (version 1)
  4. Accepted Manuscript updated: August 21, 2019 (version 2)
  5. Version of Record published: September 3, 2019 (version 3)
  6. Version of Record updated: December 11, 2019 (version 4)

Copyright

© 2019, Agerschou et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,322
    views
  • 833
    downloads
  • 51
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Emil Dandanell Agerschou
  2. Patrick Flagmeier
  3. Theodora Saridaki
  4. Céline Galvagnion
  5. Daniel Komnig
  6. Laetitia Heid
  7. Vibha Prasad
  8. Hamed Shaykhalishahi
  9. Dieter Willbold
  10. Christopher M Dobson
  11. Aaron Voigt
  12. Björn Falkenburger
  13. Wolfgang Hoyer
  14. Alexander K Buell
(2019)
An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils
eLife 8:e46112.
https://doi.org/10.7554/eLife.46112

Share this article

https://doi.org/10.7554/eLife.46112

Further reading

    1. Developmental Biology
    2. Neuroscience
    Melody C Iacino, Taylor A Stowe ... Mark J Ferris
    Research Article

    Adolescence is characterized by changes in reward-related behaviors, social behaviors, and decision making. These behavioral changes are necessary for the transition into adulthood, but they also increase vulnerability to the development of a range of psychiatric disorders. Major reorganization of the dopamine system during adolescence is thought to underlie, in part, the associated behavioral changes and increased vulnerability. Here, we utilized fast scan cyclic voltammetry and microdialysis to examine differences in dopamine release as well as mechanisms that underlie differential dopamine signaling in the nucleus accumbens (NAc) core of adolescent (P28-35) and adult (P70-90) male rats. We show baseline differences between adult and adolescent stimulated dopamine release in male rats, as well as opposite effects of the a6 nicotinic acetylcholine receptor (nAChR) on modulating dopamine release. The a6-selective blocker, a-conotoxin, increased dopamine release in early adolescent rats, but decreased dopamine release in rats beginning in middle adolescence and extending through adulthood. Strikingly, blockade of GABAA and GABAB receptors revealed that this a6-mediated increase in adolescent dopamine release requires NAc GABA signaling to occur. We confirm the role of a6 nAChR and GABA in mediating this effect in vivo using microdialysis. Results herein suggest a multisynaptic mechanism potentially unique to the period of development that includes early adolescence, involving acetylcholine acting at a6-containing nAChRs to drive inhibitory GABA tone on dopamine release.

    1. Neuroscience
    Jongkyun Kang, Guodong Huang ... Jie Shen
    Research Article

    Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease (PD). However, whether LRRK2 mutations cause PD and degeneration of dopaminergic (DA) neurons via a toxic gain-of-function or a loss-of-function mechanism is unresolved and has pivotal implications for LRRK2-based PD therapies. In this study, we investigate whether Lrrk2 and its functional homolog Lrrk1 play a cell-intrinsic role in DA neuron survival through the development of DA neuron-specific Lrrk conditional double knockout (cDKO) mice. Unlike Lrrk germline DKO mice, DA neuron-restricted Lrrk cDKO mice exhibit normal mortality but develop age-dependent loss of DA neurons, as shown by the progressive reduction of DA neurons in the substantia nigra pars compacta (SNpc) at the ages of 20 and 24 months. Moreover, DA neurodegeneration is accompanied with increases in apoptosis and elevated microgliosis in the SNpc as well as decreases in DA terminals in the striatum, and is preceded by impaired motor coordination. Taken together, these findings provide the unequivocal evidence for the cell-intrinsic requirement of LRRK in DA neurons and raise the possibility that LRRK2 mutations may impair its protection of DA neurons, leading to DA neurodegeneration in PD.